Developing alternative routes of immunotherapies with innovative drugs for neurodegenerative diseases.

Learn more about Tiziana   Tiziana Investor Deck   Scientific Presentations and Updates

In the Media

Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects

23 November 2022

  • Third-party research conducted by leading U.S. academic institutions published in a peer reviewed journal Frontiers in Immunology shows a favorable safety profile for intranasally administered foralumab and immunological activity in humans
  • ...
Read more

Tiziana Life Sciences Announces Near- Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

10 November 2022

-Company to host conference call via webcast at 10 am ET -

NEW YORK, November 10, 2022-- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today...

Read more

Tiziana Life Sciences to Host Investor Call

04 November 2022

NEW YORK, November 04, 2022-- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company plans to host an investor call and...

Read more

Our Mission

Our mission is to bring breakthrough therapies to patients with the aim of treating SPMS, Crohn's Disease, lung diseases and optimizing health outcomes.

Learn more

Clinical Candidates

Our major clinical assets are supported by extensive worldwide issued patents and pending patent applications covering composition of matter, formulation technologies, manufacturing processes and disease indications.



Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and neurodegenerative indications.

Learn more about Foralumab

Anti IL-6 Receptor mAb

We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for lung diseases.

Learn more about Anti IL-6R


Milciclib is the Company’s clinical candidate for the treatment in cancer indications. The company is exploring the combination of milciclib and gemcitibine in NSCLC patients with pan KRAS+ mutations.

Learn more about Milciclib

Clinical Trials

Tiziana is currently conducting clinical development programs for Foralumab, Anti IL-6R and Milciclib


Tiziana reported positive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Phase 2 patient enrollment is expected to begin in 1H 2022 for nasally administered Foralumab for the treatment of Non-active SPMS.

See more Foralumab clinical trials

Anti IL-6R mAb (TZLS-501)

Manufacturing of clinical supplies for a Phase 1 study is anticipated to be completed in 4Q 2022.


We are exploring a study to evaluate the combination of milciclib and gemcitabine in NSCLC subjects with associated pan KRAS-positive mutations.

See more Milciclib clinical trials

Tiziana Life Sciences is listed on NASDAQ